诺迪康胶囊对高脂血症患者血脂及胰岛素抵抗的影响

Influence of nuodikang capsule on the blood lipid and insulin resistance of the patients with hyperlipidemina

目的观察诺迪康胶囊对高脂血症患者血脂及胰岛素抵抗的影响。方法入选门诊高脂血症患者80例,随机分为观察组和对照组各40例。两组停用其他降脂药物达5个半衰期以上,治疗期间维持正常饮食。观察组在原有诊疗基础上加用诺迪康胶囊口服2粒,3次/d,8周,对照组不加用诺迪康胶囊。检测两组治疗前及治疗8周后血脂总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)、空腹胰岛素(FSIN)水平、计算胰岛素敏感性指数(ISI)并进行统计学分析。结果治疗前,观察组与对照组血脂总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)、空腹胰岛素(FSIN)水平无明显差异(P>0.05)。诺迪康胶囊治疗8周后,对照组治疗前后各指标无明显差异(P>0.05),观察组的TC、TG、LDH-C均有降低(P<0.05),HDL-C升高(P<0.05),空腹血糖无明显差异(P>0.05),空腹胰岛素水平降低(P<0.05),胰岛素敏感指数升高(P<0.05);与对照组比较,治疗8周后TC、TG、LDL-C、HDL-C、空腹血糖均优于对照组各指标,差异有统计学意义(P<0.05)。结论诺迪康胶囊可降高脂血症患者血脂水平,改善胰岛素抵抗。

Objective To observe the influence of nuodikang capsules on the blood lipid and insulin resistance of the patients with hyperlipidemia. Methods Eighty cases with hyperlipidemia from outpatient were selected and randomly assigned into observation group and control group with 40 cases in each. Patients from both groups suspended to take other lipid-lowering drugs for over 5 half-life periods and normal food and drinks were as maintained during the treatment period. Patients in the observation group additionally took nuodikang capsules orally at the original basis of diagnosis and treatment（2 tablets, 3 times/day, 8 weeks） while the nuodikang capsules were not given to the patients in the control group. Total cholesterol（TC）, triglycerides（TG）, low density lipoprotein cholesterol（LDL-C）, high density lipoprotein cholesterol（HDL-C）, fasting blood glucose（FBG） and fasting insulin（FSIN） level before the treatment and 8 weeks after the treatment of the two groups were compared, insulin sensitivity index（ISI） was calculated and statistical analysis were made. Results The TC, TG, LDL-C, HDL-C and FBG of the observation group had no significant differences from those of the control group before treatment（P〉0.05）. After taking nuodikang capsules for 8 weeks, the indexes of control group showed no differences（P〈0.05） before and after the treatment. TC, TG, LDH-C in the observation group decreased（P〈0.05） and HDL-C increased（P〈0.05） and FBG showed no significant differences（P〉0.05）, FSIN decreased（P〈0.05） and ISI increased（P〈0.05）; after treatment for 8 weeks, TC, TG, LDL-C, HDL-C and FBG in the observation group were all better than each index of the control group and the differences were significant（P〈0.05）. Conclusion Nuodikang capsules can decrease the blood lipid level of the patients with hyperlipidemia and improve the insulin resistance.